Spontaneous Coronary Artery Dissection (SCAD) National Swiss Registry (SwissSCAD)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Spontaneous coronary artery dissection (SCAD), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death. Timely diagnosis of SCAD as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood. In this context, we designed the SwissSCAD registry, a large, observational, prospective, cohort study, to describe the natural history of SCAD, its outcomes and its treatments.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Subject is ≥18 years of age.

• Patient presenting newly diagnosed SCAD or diagnosed with SCAD within the last 5 years.

• Subject must be willing to sign a Patient Informed Consent (PIC).

Locations
Other Locations
Switzerland
Geneva University Hospitals
RECRUITING
Geneva
Contact Information
Primary
Sophie Degrauwe, Dr
sophie.degrauwe@hcuge.ch
+41795530294
Backup
Veronique Menoni, PhD
Veronique.Menoni@hcuge.ch
+41795530917
Time Frame
Start Date: 2020-08-12
Estimated Completion Date: 2030-06-30
Participants
Target number of participants: 1000
Treatments
Retrospective patients
The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.
Prospective patients
Patients presenting at the hospital with newly diagnosed SCAD will be informed of the SwissSCAD study and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the prospective arm.
Sponsors
Leads: Dr. Sophie Degrauwe

This content was sourced from clinicaltrials.gov